Myelofibrosis Pipeline Analysis report 2019 (H1) covers more than 10 drugs currently in different phases of development. Myelofibrosis is a chronic serious disorder which disrupts the normal production of the blood cells due to the excessive scarring in the bone marrow and belongs to a group of diseases called myeloproliferative disorders. The exact cause of the disease is yet not known however, some mutations affecting proteins that work in signaling pathways in the cells may be considered as the reason. Common symptoms of myelofibrosis are splenomegaly, fatigue, paler mucous membranes, and cachexia. Diagnoses are done by blood tests, bone marrow biopsy, and imaging tests.
The report provides Myelofibrosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are AbbVie, CTI BioPharma Corp., NS Pharma,Inc, and Bristol Myers Squibb among others.
Scope:
The report provides Myelofibrosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are AbbVie, CTI BioPharma Corp., NS Pharma,Inc, and Bristol Myers Squibb among others.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction
2. Disease Overview
4. Market Dynamics
5. Pipeline Analysis/Outlook
6. Company profiling
Companies Mentioned
- AbbVie
- Constellation Pharmaceuticals
- CTI BioPharma Corp.
- Celgene Corp
- Acceleron Pharma, Inc.
- Celgene Corp
- NS Pharma,Inc
- Astra Zeneca
- Bristol Myers Squibb
- Stemline Therapeutics
- Kartos Therapeutics
Methodology
LOADING...
